Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Hopfgartner

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Clinical Pharmacology|July 7, 1999
Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteersC Weber, R Schmitt, H Birnboeck, et al.
Clinical Pharmacology and Therapeutics|August 1, 1996
Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjectsC Weber, R Schmitt, H Birnboeck, et al.
Journal of Clinical Pharmacology|November 1, 1996
Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteersJ Zhi, A T Melia, C Funk, et al.
Analytical and Bioanalytical Chemistry|November 24, 2017
The scope of Analytical and Bioanalytical Chemistry (ABC)H Cui, P Garrigues, G Gauglitz, et al.
British Journal of Pharmacology|July 2, 2010
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyC F Samer, Y Daali, M Wagner, et al.
British Journal of Pharmacology|July 2, 2010
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneC F Samer, Y Daali, M Wagner, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Clinical Pharmacology|July 7, 1999
Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteersC Weber, R Schmitt, H Birnboeck, et al.
Clinical Pharmacology and Therapeutics|August 1, 1996
Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjectsC Weber, R Schmitt, H Birnboeck, et al.
Journal of Clinical Pharmacology|November 1, 1996
Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteersJ Zhi, A T Melia, C Funk, et al.
Analytical and Bioanalytical Chemistry|November 24, 2017
The scope of Analytical and Bioanalytical Chemistry (ABC)H Cui, P Garrigues, G Gauglitz, et al.
British Journal of Pharmacology|July 2, 2010
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyC F Samer, Y Daali, M Wagner, et al.
British Journal of Pharmacology|July 2, 2010
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneC F Samer, Y Daali, M Wagner, et al.
Pageof 3